IMRX
Immuneering Corp. Class A · NASDAQ
- Sector Health Technology
- Industry Pharmaceuticals: Major
- Website immuneering.com
- Employees(FY) 67
- ISIN US45254E1073
Performance
-5.77%
1W
-20.11%
1M
-77.73%
3M
-71.4%
6M
-80.0%
YTD
-83.03%
1Y
Profile
Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 currently in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.
Technical Analysis of IMRX 2024-05-10
Overview:
In analyzing the technical indicators for IMRX over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible stock price movement in the coming days.
Trend Analysis:
- Moving Averages (MA): The 5-day Moving Average (MA) has been fluctuating around the c...
Recent News & Updates
- 2024-05-17 00:50
- 2024-05-07 10:55
IMRX Stock Earnings: Immuneering Misses EPS for Q1 2024(Investorplace)
- 2024-05-07 04:05
- 2024-05-06 04:30
Immuneering Recognizes Melanoma Awareness Month(Globenewswire)
- 2024-04-09 00:00
- 2024-04-03 04:05
- 2024-03-26 20:00
- 2024-03-17 23:02
- 2024-03-13 19:00
- 2024-03-11 20:00
- 2024-03-10 20:00
- 2024-03-05 19:00
- 2024-03-05 04:00
- 2024-03-03 19:00
- 2024-03-03 06:01
- 2024-02-29 19:00
- 2024-02-19 19:00
- 2024-02-14 02:45
- 2024-01-31 19:00
- 2023-12-11 19:00
- 2023-11-20 03:05
- 2023-11-09 03:05
- 2023-10-12 04:05
- 2023-10-04 04:05
- 2023-09-05 20:00
- 2023-08-03 04:05
- 2023-08-01 18:09
- 2023-07-04 21:55
- 2023-06-04 20:00
- 2023-05-29 20:00
Page 1 of 4
previousnext